New Asian Bridging Clinical Research Unit has been opened by Contract Research Organization WCCT Global
WCCT Global, a full service CRO headquartered in Southern California announced today the opening of a new Asian Bridging clinical research site. This state of the art facility has been reconfigured to provide for 30 semi-private rooms to give each clinical trial volunteer a more comfortable experience for extended in-house stays. This dedicated clinical pharmacology unit is located in Orange County, California which is a central location enabling access to the many Asian populations that reside in the surrounding communities. WCCT Global has been conducting Asian bridging clinical trials for over 10 years and has conducted the largest Asian bridging clinical trial ever done in the United States. Over the past 5 years WCCT Global has conducted over 60 Asian Bridging studies and recruited over 1600 Asian volunteers during this 3-year period. Interestingly, over 20% of those trials have required extended overnight confinement (> 4 days) to the research center. Therefore, the availability of this "built-to-suit" extended stay facility will provide a more comfortable and attractive setting for research participants. WCCT Global reports that based upon volunteer exit survey results, safety and comfort are the 2 most important determinants for a volunteer's decision to participate in "extended stay" clinical trials. Therefore, WCCT Global has also designed this new facility to accommodate every aspect of a volunteer's research experience, from the meals they are provided to the utilization of their free-time in order to make the volunteers stay as enriched, safe and comfortable as possible.
WCCT Global's Chief Operating Officer, Jon Rojas, stated "We decided to reconfigure this research center in response to our study participants' survey responses. I think that we have created an extended-stay research center that will provide the safe and comfortable environment that our Asian bridging study volunteers have expressed the desire for. We wanted a unit that can make our volunteers as comfortable as possible while offering our clients the best ethno-bridging solution available."
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.